Flanax (Naproxen) 550 Mg
Flanax (Naproxen) 550 mg
All information contained in the article on Flanax is intended for informational purpose and is not intended in any way, replace the guidance of a medical professional or serve as a recommendation for any treatment. Decisions concerning the treatment of patients with Flanax must be made by authorized personnel, considering the characteristics of each patient.
Flanax (naproxen sodium) is contraindicated in patients with hypersensitivity to naproxen or naproxen sodium. To the possibility of cross-reactivity, Flanax (naproxen sodium) should not be administered to patients in whom aspirin or other pain relievers and / or NSAIDs induce syndrome of asthma, rhinitis, nasal polyps or urticaria. The two types of reactions can be life threatening. In these patients reported severe anaphylactic reactions to naproxen. Flanax (naproxen sodium) is also contraindicated in patients with active peptic ulcer disease and gastrointestinal bleeding active.
Adverse Reactions / Side Effects Flanax
The following events are the most commonly reported: abdominal pain, thirst, constipation, diarrhea, dyspnea, nausea, stomatitis, heartburn. There may be drowsiness, dizziness, headaches, dizziness, rashes, itching, sweating. We also reported the occurrence of auditory and visual disturbances, tinnitus, palpitations, edema, dyspepsia, purpura. They also reported the following adverse effects: functions Gastrointestinal abnormalities in liver function, colitis, esophagitis, and bleeding or perforation. Hematemesis, hepatitis, jaundice, melena, gastrointestinal ulceration and non-peptic ulcer, pancreatitis, ulcerative stomatitis, vomiting.
Renal Function: hematuria, hyperkalemia, interstitial nephritis, nephrotic syndrome, kidney disease, renal failure, renal papillary necrosis, increased serum creatinine.
Functions Hematologic: agranulocytosis, hemolytic and aplastic anemia, eosinophilia, leukopenia, thrombocytopenia.
Functions in the Central Nervous System: aseptic meningitis, cognitive dysfunction, seizures, depression, inability to concentrate, insomnia, myalgia, malaise, muscle weakness, sleep abnormalities.
Functions Dermatologic: alopecia, epidermal necrolysis, erythema multiforme and nodosum, lichen planus, rash, Stevens-Johnson syndrome, urticaria, photosensitive reactions, epidermolysis bullosa. If there is skin fragility, blistering or other symptoms, treatment should be discontinued and the patient monitored.
Functions Respiratory: asthma, eosinophilic pneumonitis.
Functions Cardiovascular: congestive heart failure, hypertension, pulmonary edema and vasculitis. You may experience anaphylactic reactions, angioneurotic edema, and pyrexia. Reactions can also occur such as corneal opacity, papillitis, retrobulbar optic neuritis and papilledema. Interference with laboratory tests: It is suggested that therapy with Flanax (naproxen sodium) is temporarily discontinued 48 hours before carrying out tests of adrenal function because Flanax (naproxen sodium) may incidentally interfere with some evidence of steroid 17 - ketogenic. Similarly, Flanax (naproxen sodium) can interfere with some tests for urinary 5-hydroxyindolacetic acid. Naproxen decreases platelet aggregation, increasing bleeding time. This effect must be taken into account in determining the bleeding time.
Flanax - Dosage
Adults Flanax (naproxen sodium) can be administered on an empty stomach or with meals. Adult use indications analgesic, antipyretic and anti-inflammatory - 550 mg initially, followed by 275 mg at intervals of 6-8 hours. Alternatively, Flanax (naproxen sodium) has also been shown to be effective when administered as single daily dose of 550-1100 mg, administered in the morning or evening. To reduce menstrual blood loss: 825-1375 mg daily in two doses on the first day of bleeding, 550 - 1100 mg daily, in the following days, in two doses, if necessary, for a period not exceeding five days. Migraine prophylaxis: The recommended dose is 550 mg twice daily, under medical supervision, at intervals of 12 hours. No improvement in 4-6 weeks, the drug should be discontinued. For the treatment of migraine: 825 mg the first symptom of impending crisis. Additional doses of Flanax (naproxen sodium) 275 to 550 mg may be taken during the day, if necessary, but not before half an hour after the initial dose. The total dose should not exceed 1375 mg